Abstract
CAR T cell therapy is a new treatment option for patients with diffuse large B cell lymphoma. Chimeric antigen receptor (CAR) is a combination of antibody and T cell receptor.
CAR represent genetically modified T cell receptor whose gene could be transfected to autologous T cell of the patients (CAR T lymphocyte is constructed). New therapy, axicabtagene ciloleucel, based on genetically modified CAR T lymphocytes was established.
Efficacy and safety of administering CAR T lymphocytes to patients with diffuse large B cell lymphoma was assessed in ZUMA-1 clinical trial.